Sonoclot analyzer has been widely used in many countries. But the reference intervals provided by the manufacturer were derived from only 45 participants, and there was no cut-off value for transfusion for Sonoclot an...Sonoclot analyzer has been widely used in many countries. But the reference intervals provided by the manufacturer were derived from only 45 participants, and there was no cut-off value for transfusion for Sonoclot analysis. This study aimed to establish reference intervals and transfusion criterion for Sonoclot analysis. Volunteers were recruited from healthy Chinese adults and patients undergoing cardiac surgery. Blood samples were withdrawn from forearm vein and measured for activated clotting time（ACT）, clot rate（CR）, platelet function（PF）, activated partial thromboplastin time（APTT）, fibrinogen concentration（FIB）, and platelet count（PLT）. The reference intervals were determined by the nonparametric method. Cut-off values were determined by the receiver operating characteristics curve. A total of 135 healthy volunteers and 281 patients were enrolled. The 95% reference intervals were 96–195 s, 22–51 signal U/min, 〉1.6 for ACT, CR, PF respectively. In the 281 patients, the results of APTT, FIB, PLT, ACT, CR, and PF ranged from 20.5–300.0 s, 0.28–4.11 g/L,（19.0–387.3）×109/L, 80–514 s, 2.9–74 signal U/min, and 0.1–5.1 respectively. The cut-off values for transfusion were 〉208, ≤14, and ≤1.3 for ACT, CR, PF respectively. The cut-off values of Sonoclot analysis were within the manufacturer＇s reference intervals, while they were outside the reference intervals established in this study. The results suggested that the manufacturer＇s reference intervals were not suitable for Chinese. The reference intervals and cut-off values established in this study will be helpful to Chinese patients.展开更多
Objective： To detect the anticoagulation and antiplatelet effects of different concentrations of puerarin, heparin sodium and tirofiban hydrochloride on the blood samples of healthy volunteers by Sonoclot coagulation...Objective： To detect the anticoagulation and antiplatelet effects of different concentrations of puerarin, heparin sodium and tirofiban hydrochloride on the blood samples of healthy volunteers by Sonoclot coagulation and platelet function analyzer. Methods： Peripheral blood samples were extracted from 20 healthy volunteers, followed by adding different concentrations of puerarin, heparin sodium and tirofiban hydrochloride. Samples were detected for activated clotting time（ACT）, clot rate（CR） and platelet function（PF） by Sonoclot coagulation and platelet function analyzer instrument. Results： For puerarin and heparin sodium, the values of ACT gradually increased, and the values of CR and PF gradually decreased with increasing in drug concentration. There was a linear（or log linear） relationship between ACT, CR, PF value and drug concentration（P〈0.01）. Corresponding to each value, a regression equation was obtained. For tirofiban hydrochloride, the values of ACT and CR had no significant changes, while PF values gradually decreased with concentration increasing. There was also a linear relationship between PF values and concentrations of tirofiban hydrochloride（P〈0.01）. Under the same ACT values, the puerarin corresponding CR values（CR = e^（-0.0062） ACT＋4.31, P〈2.2 e^（-16）） were always higher than the corresponding values（CR = e-^（0.0028） ACT＋2.79, P-value〈2.2 e^（-16）） of heparin sodium. For high concentrations of puerarin（e.g. 3.8 mg/600 μL） and tirofiban hydrochloride（e.g. 0.8 μg/600 μL）, PF values had no significant difference. However, PF values for high puerarin concentration had a larger variance. Conclusions： Puerarin has similar anticoagulant and antiplatelet effects with the heparin sodium, and may have a lower hemorrhage risk than heparin sodium when obtained the same anticoagulation effect in the concentration range of this experiment. In addition, for high concentration, puerarin had the same antiplatelet function as tirofiban hydrochloride but with a larger individual variability.展开更多
文摘Sonoclot analyzer has been widely used in many countries. But the reference intervals provided by the manufacturer were derived from only 45 participants, and there was no cut-off value for transfusion for Sonoclot analysis. This study aimed to establish reference intervals and transfusion criterion for Sonoclot analysis. Volunteers were recruited from healthy Chinese adults and patients undergoing cardiac surgery. Blood samples were withdrawn from forearm vein and measured for activated clotting time（ACT）, clot rate（CR）, platelet function（PF）, activated partial thromboplastin time（APTT）, fibrinogen concentration（FIB）, and platelet count（PLT）. The reference intervals were determined by the nonparametric method. Cut-off values were determined by the receiver operating characteristics curve. A total of 135 healthy volunteers and 281 patients were enrolled. The 95% reference intervals were 96–195 s, 22–51 signal U/min, 〉1.6 for ACT, CR, PF respectively. In the 281 patients, the results of APTT, FIB, PLT, ACT, CR, and PF ranged from 20.5–300.0 s, 0.28–4.11 g/L,（19.0–387.3）×109/L, 80–514 s, 2.9–74 signal U/min, and 0.1–5.1 respectively. The cut-off values for transfusion were 〉208, ≤14, and ≤1.3 for ACT, CR, PF respectively. The cut-off values of Sonoclot analysis were within the manufacturer＇s reference intervals, while they were outside the reference intervals established in this study. The results suggested that the manufacturer＇s reference intervals were not suitable for Chinese. The reference intervals and cut-off values established in this study will be helpful to Chinese patients.
基金Supported by the 1st-class General Financial Grant from the China Postdoctoral Science Foundation(No.2016M590188)
文摘Objective： To detect the anticoagulation and antiplatelet effects of different concentrations of puerarin, heparin sodium and tirofiban hydrochloride on the blood samples of healthy volunteers by Sonoclot coagulation and platelet function analyzer. Methods： Peripheral blood samples were extracted from 20 healthy volunteers, followed by adding different concentrations of puerarin, heparin sodium and tirofiban hydrochloride. Samples were detected for activated clotting time（ACT）, clot rate（CR） and platelet function（PF） by Sonoclot coagulation and platelet function analyzer instrument. Results： For puerarin and heparin sodium, the values of ACT gradually increased, and the values of CR and PF gradually decreased with increasing in drug concentration. There was a linear（or log linear） relationship between ACT, CR, PF value and drug concentration（P〈0.01）. Corresponding to each value, a regression equation was obtained. For tirofiban hydrochloride, the values of ACT and CR had no significant changes, while PF values gradually decreased with concentration increasing. There was also a linear relationship between PF values and concentrations of tirofiban hydrochloride（P〈0.01）. Under the same ACT values, the puerarin corresponding CR values（CR = e^（-0.0062） ACT＋4.31, P〈2.2 e^（-16）） were always higher than the corresponding values（CR = e-^（0.0028） ACT＋2.79, P-value〈2.2 e^（-16）） of heparin sodium. For high concentrations of puerarin（e.g. 3.8 mg/600 μL） and tirofiban hydrochloride（e.g. 0.8 μg/600 μL）, PF values had no significant difference. However, PF values for high puerarin concentration had a larger variance. Conclusions： Puerarin has similar anticoagulant and antiplatelet effects with the heparin sodium, and may have a lower hemorrhage risk than heparin sodium when obtained the same anticoagulation effect in the concentration range of this experiment. In addition, for high concentration, puerarin had the same antiplatelet function as tirofiban hydrochloride but with a larger individual variability.
